CLINICAL TRIAL: HUPERZINE A TRIAL

临床试验：石杉碱甲试验

• 批准号: 7724997
• 负责人: RUTH MULNARD MCCARGAR
• 金额: $ 0.23万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-12-01 至 2008-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7724997
• 关键词: Aging; Alzheimer' s Disease; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Dose; Funding; Grant; Institutes; Institution; Patients; Phase II Clinical Trials; Placebos; Population; Randomized; Research; Research Personnel; Resources; Safety; Source; United States National Institutes of Health; Week; cognitive function; huperzine A

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a Phase II clinical trial supported by the National Institute on Aging and Marco Hi-Tech for a twenty-four week period of exposure in which patients with Alzheimer's disease are randomized to receive escalating doses of Huperzine A versus placebo to evaluate the safety, tolerability, and impact on cognitive function of this agent in this population.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这是由美国国家老化研究所和Marco Hi-Tech支持的II期临床试验，经过二十四个星期的暴露期，在该期间，阿尔茨海默氏病的患者被随机分配，以接收不断升级的Huperzine A Versus Anterbo剂量，以评估该人在这个人群中对该药物的安全性，对安全性的影响。